Home / Prepare Your Business for Sale / Medical Spa

How to Prepare Your Medical Spa for a Sale or Exit (2026)

Updated April 2026 · CT Acquisitions

Most medical spa owners decide to sell, hire a broker, and find out 90 days later that their business is worth 30% to 50% less than they thought. The owners who get the top-quartile multiple start preparing 24 to 36 months before they ever talk to a buyer. This guide is the 36-month playbook for how to prepare your medical spa for a sale or exit. It covers what private equity actually buys in aesthetics, the 12 levers that move medspa multiples, the documents PE will ask for before they send an indication of interest, and the deal-killers that re-trade medical spa transactions during confirmatory diligence. Every number cites its source. Every recommendation comes from how the most active aesthetics buyers in 2026 actually behave.

If you are 6 to 36 months from a possible exit, this is the work that turns a 4x EBITDA outcome into a 9x EBITDA outcome. On a $2M EBITDA medical spa, that is the difference between an $8M sale and an $18M sale. Whether you want to prepare your medical spa for a sale to private equity, prepare your medical spa for an exit to a strategic MSO, or simply maximize value over the next 1 to 3 years before going to market, the work below applies. Medical spa is the highest-multiple healthcare-services PE lane because it is cash-pay (no insurance billing friction), membership-recurring, and high-margin (BOTOX and filler injectables run 70%+ gross margin). Platform-quality medspas trade at 10x to 14x+ EBITDA.

What Private Equity Actually Buys in Medical Spa (2026)

30+ active PE platforms are competing for quality independent medspas in 2026, against an industry where over 90% of practices remain independently owned and only 3% to 4% are PE-consolidated (American Med Spa Association 2024 State of the Industry Report; Physician Growth Partners “Medical Aesthetics Private Equity” 2025 update). The US medspa market sits above $18 billion in 2024 and is projected to reach $49 billion by 2030 at a 15% CAGR (Grand View Research 2024; Ankura MedSpa sector financial DD perspective 2025). M&A deal announcements grew from a handful in 2019 to 2020 to 50+ per year in 2023 and 2024 (Scope Research, “Med Spa and Aesthetics Valuation Multiples and M&A Trends 2025”). The sponsor money flowing in is not random. PE buys specific profiles, and the profile you build determines the multiple you get.

The PE-attractive medical spa profile

• EBITDA threshold for a platform-quality deal: $1M to $4M is the band where sponsor-backed platforms run a competitive process. Below that, you are an add-on inside a roll-up. Above $4M, you become an attractive bolt-on for the regional platforms. Above $15M revenue with multi-provider depth, you are a platform candidate yourself.
• Recurring membership revenue: 30% or higher is the line between commodity and premium. Industry-average membership penetration sits at 14% (Pabau 2025; Vagaro 2026). Medspas at 30%+ recurring trade at the top end of the 7x to 9x band per FOCUS Investment Banking 2026; below 14% you cluster with the 3x to 6x add-on tier (Scope Research 2025).
• Geography: Florida, Texas, California, Arizona, North Carolina, Tennessee, and major Sun Belt and suburban metros are where 2026 sponsor demand concentrates. Florida, Texas, and California led 2025 PE activity (AmSpa “Med Spa M&A and Private Sales: A Look Back at 2025”).
• Provider concentration: Provider concentration replaces customer concentration as the lead key-person risk. No single injector above 25% of injectable revenue. Master-injector flight risk is the single biggest issue buyers test for (NERO “Med Spa M&A Record 2026”).
• Multi-provider depth: 2+ W-2 injectors with cross-pollinated patient panels, plus aesthetician and laser tech depth. Provider utilization at 75% to 85% for injectors and 65% to 80% for aestheticians (CFO Pro Analytics 2025; Boulevard “Medspa Nurse Salary Guide” 2026).
• Owner role: Owner is in management, not the highest-volume injector. GM in place 12+ months pre-sale. Owner doing under 30 hours/week of clinical work and under 20% of injectable revenue.
• Compliance: Documented MSO/PC structure in every operating state. Written medical director agreement with delegation protocols and FMV fee. Authorized-distributor procurement records for all BOTOX and filler. W-2 classification for clinical staff.

Active medical spa PE / MSO platforms in 2026

The list below covers the most active sponsor-backed and MSO-backed medspa platforms in the 2024-2026 cycle. This is who will see your teaser. Sources include sponsor press releases, PrivSource, PitchBook, AmSpa news, Skytale Group transaction notes, BC Partners press releases, PR Newswire and Business Wire announcements through May 2026.

Add to that list the strategic acquirers. AbbVie / Allergan Aesthetics (NYSE: ABBV) manufactures BOTOX Cosmetic, Juvederm, SkinVive, SkinMedica, and operates the Alle Skincare Society loyalty program plus Allergan Partner Privileges. Allergan does not buy service-channel practices at scale, but Allergan tier status and authorized-distributor procurement records are gating items in PE diligence. Galderma (SIX: GALD) manufactures Restylane, Dysport, Sculptra, and Alastin; operates Aspire Galderma Rewards. Revance Therapeutics (combined with Crown Laboratories Feb 2025) manufactures DAXXIFY and the RHA filler collection; runs EDGE by Revance as the practice partner platform. BeautyHealth (NASDAQ: SKIN, parent of HydraFacial) is a device + consumables play, not a service-channel acquirer. SBC Medical Group Holdings (NASDAQ: SBC), the Japanese-rooted strategic, took a minority stake plus collaboration framework in OrangeTwist January 2026, the first public-company route into US medspa via minority partnership. Aspen Dental Management has built Chapter Aesthetic Studio to 22+ studios alongside its 1,100+ dental offices, ClearChoice, Motto, and WellNow Urgent Care. Dermatology consolidators (Anne Arundel Dermatology, Schweiger Dermatology Partners, Epiphany Dermatology, US Dermatology Partners, Pinnacle Dermatology, DermCare Management) occasionally cross-buy when a target has integrated cosmetic services. Note: the aesthetic manufacturers sell product, they do not buy service practices, so PE/MSO remains the dominant exit channel for sub-$25M EBITDA medspas.

Medical Spa Valuation Multiples in 2026 (What You Are Actually Worth)

The multiple a buyer pays comes down to your size, your recurring revenue mix, your provider depth, your geographic fit, and (most uniquely in medspa) your compliance structure. Here is the 2026 range, cross-referenced from FOCUS Investment Banking, Breakwater M&A, Scope Research, AmSpa, Physician Growth Partners, and First Page Sage.

SDE multiples (smaller, owner-operated)

EBITDA multiples (PE-attractive size)

Adjacent sector comps for cross-reference: dermatology 5.4x, medical practices broadly 5.6x, plastic surgery 7.3x at the $1M to $3M EBITDA band; dermatology platforms 12x to 15x and plastic surgery platforms 9x to 12x at scale (First Page Sage 2025 Healthcare Multiples Report; FOCUS Healthcare EBITDA Multiples Dashboard 2026). Medspa multiples cluster between dermatology and plastic surgery at the single-site level and approach plastic surgery platform multiples at the platform tier.

Recent disclosed medical spa transactions (2024-2026)

Sources: Business Wire (Dec 1, 2025; Feb 19, 2026; May 8, 2024); PR Newswire / Morningstar (May 13, 2026); PR Newswire (Jan 2026; Sept 2025; May 2025); PharmiWeb (Jan 5, 2026); BC Partners + Princeton Equity Group press releases; Hidden Harbor Capital Partners press release 2025; AmSpa news; American Spa; Skytale Group transaction notes; PrivSource; VSS Capital Partners. Deal structure norms in 2025: most medspa transactions structured as 60% cash at close + 40% rollover equity, ranging up to 80% cash + 20% rollover, with holdbacks and earnouts standard, particularly tied to provider retention (AmSpa “Med Spa M&A and Private Sales: A Look Back at 2025”).

The 12 Value Levers That Move Your Multiple (Ranked by Impact)

These are the levers that move medical spa multiples in the 24 months before a sale. Each one has a current state, a target state, and an estimated financial impact. The ordering is by dollar impact per unit of effort, based on cross-source synthesis from FOCUS Bankers 2026, Breakwater M&A 2026, NERO 2026, Hinshaw & Culbertson 2025, Practice Transitions Group, Aesthetic Brokers, and Ankura 2025.

Lever 1: Push membership penetration to 30%+ of revenue

Current: No formal membership program, or membership contributes under 14% of revenue (industry average per Pabau and Vagaro 2025). Target: Membership revenue 30% to 40% of total with renewal rate above 80%. Plan mix includes a premium tier with banked monthly credits. Impact: 0.5x to 1.0x multiple uplift at the FOCUS Bankers 30%+ recurring threshold. On a $1.5M EBITDA medspa, that delta is $750K to $1.5M of sale price (FOCUS Bankers 2026; Breakwater M&A 2026). Members visit 2.9x more often and spend 35% more per visit than non-members (Boulevard “Average Med Spa Revenue” 2025; ProSpyrMed). A member is worth 4.8x more lifetime value than a per-visit client (ProSpyrMed). Medspa membership sales grew 13% year over year in 2025 (Vagaro 2026). How: Auto-renew monthly billing with stored card. Banked credit that rolls 60 to 90 days. Tiered plans ($99/mo basic, $199/mo premium, $399/mo VIP). Front-desk script to convert new patients into membership at first visit. Allowing 2 to 3 months of rollover credit with a cap reduces cancellation churn 20% to 30% (Delam / Regulr.ai 2026).

Lever 2: Move the owner out of the injector chair

Current: Owner is the highest-volume injector, doing 40%+ of injectable revenue, also running operations. Target: Owner doing under 20% of injectable revenue. GM or practice manager in place 12+ months pre-sale. 2 to 3 W-2 injectors with cross-pollinated patient panels. Impact: Owner / provider concentration is the single most-cited multiple haircut in medspa valuation literature. Buyers spend significant time on provider compensation, employment agreements, and non-competes (NERO 2026; Hinshaw 2025). Removing key-person risk shifts pricing from SDE to premium EBITDA multiples; estimate +1.0x to 1.5x for credible succession (Breakwater M&A 2026). On a $1M to $3M EBITDA medspa, that is $1M to $4.5M of incremental price. How: Hire GM 18 to 24 months pre-sale ($120K to $180K + bonus typical). Hire 2 to 3 W-2 injectors and actively cross-pollinate the patient base. Build a patient-handoff playbook. Take a 2-week unplugged vacation as the stress test.

Lever 3: Get on a modern medspa EMR and run a real monthly close

Current: AestheticsPro Lite, Vagaro, Mindbody, or no medspa EMR at all. QuickBooks Online with no service-line P&L. No monthly close. Target: Aesthetic Record, Boulevard, Symplast, Nextech, or Pabau in place 18+ months. Monthly close within 15 days. Real KPI dashboard covering average ticket, visits per patient per year, member MRR + ARR + churn, injector utilization, aesthetician utilization, new patient acquisition cost by channel, and review velocity. Impact: Estimate +0.5x to 1.0x multiple uplift, mostly from data-room speed and credibility during diligence. Nextech reports 26% increase in consultation-to-client conversions for medspas on the platform (ProSpyrMed “Best CRM and EMR Systems”). Boulevard medspa usage grew 640% over two years (ProSpyrMed). How: Budget $5K to $50K implementation + per-provider monthly license ($195/mo Boulevard up to $650/mo for 4D EMR; Symplast around $300/mo). Force provider adoption by tying chart completion to commission payout.

Lever 4: Drive average ticket and pricing discipline

Current: Average ticket below $400; injectors discounting on units; no annual pricing review. Target: Average ticket $500+ (top-tier benchmark is $672.50 per FinancialModelsLab 2025; $536 per Ankura 2025 industry-wide; top-tier medspa ticket recovered to $454 to $484 in 2025 per Zenoti Benchmark Report). Injectors cannot discount unit price. Annual price book refresh. Impact: Direct EBITDA growth. A $2M revenue medspa with 60% injectable mix that lifts average injectable ticket by $75 (15%) adds roughly $180K in revenue, with most of that dropping to EBITDA at injectable gross margins of 70%+. That EBITDA growth then gets multiplied at sale at 5x to 7x = $900K to $1.26M of additional sale price. How: Flat-rate pricing by unit (BOTOX per unit, fillers per syringe), no provider discretion. Consult-based pricing for laser and device packages. Quarterly price book review. Pre-treatment consultations that anchor on a treatment plan, not a single visit.

Lever 5: Build a 3-pillar service mix (injectables + memberships + wellness)

Current: 70%+ injectable revenue; no GLP-1 program; no memberships; no wellness line. Target: 50% to 60% injectables (BOTOX, Dysport, DAXXIFY + Juvederm, Restylane, RHA fillers) + 15% to 25% memberships + 10% to 20% wellness (GLP-1 weight-loss, IV therapy, hormone therapy) + 10% to 15% device/laser (CoolSculpting, Morpheus8, Sciton BBL, HydraFacial) + 8% to 15% skincare retail (Skinceuticals, Obagi, Alastin, SkinMedica). Impact: Diversification reduces buyer’s perceived single-product risk. GLP-1 is the fastest-growing revenue line in medspas with 70% to 85% gross margin on basic-tier compounded semaglutide (ScaleHaven 2026; Ankura 2025). Skincare retail runs 50% to 60% gross margin and typically 8% to 15% of total revenue at a healthy spa. Estimate +0.5x to 1.0x for a credibly diversified mix vs. single-product concentration. Note: PE will discount GLP-1 revenue heavily if it depends on FDA shortage carve-outs that may end (Ankura 2025). How: Add GLP-1 program with state-board-compliant prescribing structure. Layer membership tier that includes monthly facial or skincare credit. Add hormone therapy and IV menu if state-compliant.

Lever 6: Lock down the medical director arrangement and CPOM structure

Current: Handshake medical director who has not examined patients, lent name to the practice, no written delegation protocols. Or owner is a non-physician operating without proper MSO/PC structure in a CPOM-restrictive state. Target: Documented MSO/PC structure (physician owns the PC; non-physician owns the MSO). Written delegation protocols per procedure category (injectables, lasers, RF/microneedling, IV therapy, weight-loss prescribing). Medical director with state-board-required involvement (varies by state). MSO management fee at FMV (fixed or cost-plus is safest; percentage-of-revenue allowed in some states like CA but banned in others like NY) (Cohen Healthcare Law 2025; Permit Health 50-State Guide; Guardian Medical Direction). Impact: Binary. Improper structure in CA, NY, TX, or other restrictive states means the practice is operating illegally and the acquirer walks. Compliant structure preserves the deal. NERO 2026 calls compliance “the new deal-killer.” Hinshaw 2025: “Issues in any of these areas do not just reduce your multiple, they can cause buyers to walk away entirely.” How: Engage healthcare counsel (Cohen Healthcare Law, Spencer Fane, Hinshaw & Culbertson, ByrdAdatto, Holt Law all run medspa CPOM restructure engagements). Budget $25K to $75K legal restructure + ongoing $30K to $80K annual medical director fee at FMV. Get a written FMV opinion on the MD fee.

Lever 7: Provider retention + W-2 reclassification

Current: Injectors and aestheticians on 1099 to avoid payroll tax, weak or unenforceable non-competes, no written non-solicit, no provider career ladder. Target: All clinical staff W-2 (medical-supervision requirements push this; 1099 medical professionals raise CPOM concerns). Written non-compete + non-solicit appropriate to state enforceability (CA does not enforce non-competes; FL and TX enforce with limits). Provider career ladder: Junior Injector, Senior Injector, Lead Injector, Clinical Director. Impact: Misclassification is a deal-killer in confirmatory DD. IRS settlements range $10K to $100K+ per misclassified worker once back taxes, penalties, interest, and legal cost are aggregated (Liguori Accounting 2026; Weitz Morgan TX 2026). PE buyers will commission a forensic classification review. Provider retention separately drives the multiple: if key staff walk during DD or immediately post-acquisition, valuation collapses (NERO 2026). How: Reclassify clinical staff to W-2 12+ months pre-sale. Settle any back-tax exposure proactively. Build the career ladder. Train at least 2 backup injectors on every high-volume patient.

Lever 8: EBITDA add-back hygiene and clean owner expenses

Current: Owner mixes personal expenses through the business with no documentation; related-party rent at above-FMV; related-party MD fee at non-FMV; no add-back schedule. Target: Every potential add-back documented as it happens with the underlying invoice. Related-party rent restruck to FMV with appraisal. Related-party MD fee restruck to FMV with written legal opinion. Impact: Every defensible dollar of adjusted EBITDA gets multiplied. On a 6x multiple, $100K of clean add-backs equals $600K of sale price (Morgan & Westfield QoE guide; Practice Transitions Group). Defensible medspa add-backs include owner compensation above market (if a clinical director would cost $250K and the owner takes $500K, $250K adds back), owner-related medical director fees being adjusted to FMV (often $30K to $80K annual MD fee), legal fees tied to one-time CPOM restructure, non-recurring equipment write-offs (a laser device sold at loss), rebrand or website costs, COVID-era ERC if not yet booked. Buyers reject aggressive add-backs during QoE, which directly reduces price. How: Monthly add-back log starting today. Document the business purpose of every charge. Get an FMV rent appraisal if the owner owns the real estate. Get an FMV medical director fee opinion.

Lever 9: Working capital + deferred revenue normalization

Current: Cash-basis accounting; prepaid packages, gift cards, and membership prepayments commingled with revenue; no deferred revenue tracking; aggressive year-end inventory buys for Allergan rebate tiers. Target: Accrual basis aligned to ASC 606; deferred revenue isolated by source (prepaid packages, gift cards, membership prepayments, loyalty point liability); inventory normalized to TTM average. Impact: Deferred revenue is the single most disputed working capital item in medspa M&A (Auxo Capital Advisors “Working Capital Peg” 2025; Ankura 2025). Sellers argue it is normal NWC; buyers argue it is debt-like because they inherit the obligation to deliver services without receiving new cash. Poorly tracked deferred revenue lets the buyer set a higher peg (subtracting from purchase price) or move it entirely to net debt. Estimate: poorly managed deferred revenue can cost 3% to 8% of enterprise value at close in medspa, higher than the 2% to 5% range typical in service businesses generally. How: Get on accrual now. Track deferred revenue by source line. Build a 36-month membership liability schedule. Time large inventory rebate buys to fall in the trailing period, not the closing month.

Lever 10: Real estate decision (own or lease, and the sale-leaseback option)

Current: Owner-occupied real estate held in same entity as the operating business, or in an LLC at above-FMV rent. Target: Real estate in a separate LLC at FMV NNN lease to the operating company, with a clear path for the buyer to either assume the lease or buy the real estate via sale-leaseback. Impact: Separating real estate often lifts the implied EBITDA multiple on the operating business because the buyer is not forced to underwrite real estate exposure. A sale-leaseback can convert up to 100% of property market value as cash vs. 70% to 80% LTV via traditional financing (Plante Moran, Northmarq sale-leaseback primers; W. P. Carey). Estimated impact: holding real estate separately at FMV typically adds 0.5x to 1.0x to the operating company multiple. How: Get an FMV market rent study now. Restruck rent to FMV. Decide before going to market whether the real estate is part of the deal or held back.

Lever 11: Allergan and Galderma partner tier + Alle loyalty integration

Current: Not in Allergan Partner Privileges or Galderma Aspire Galderma Provider Rewards tier programs, or in a low tier. Patients not enrolled in Alle Skincare Society or Aspire. Target: Diamond/Platinum Allergan tier (requires meaningful annual BOTOX/Juvederm volume) and integrated Aspire for Galderma fillers. 60%+ injectable-receiving patients enrolled in Alle. Impact: Tier status drives wholesale rebate dollars and gives the practice an Allergan-validated brand signal in PE diligence. The Alle program (changed Sept 2024 to a points-redeemable model similar to Starbucks) materially impacts patient retention; practices that integrate the patient redemption flow see higher LTV. Practices that get dropped from Allergan accounts for buying via gray market lose access entirely and become much harder to sell (AmSpa “A Black Market for Botox?”; FDA counterfeit Botox warning April 2024; Maven FP “How Will the Alle Rewards Program Changes Impact Your Practice”). Estimate: +0.25x to 0.5x multiple via lifted LTV and procurement validation; access to authorized supply is binary. How: Push annual volume to qualify for higher tier. Front-desk script to enroll every injectable patient in Alle at check-in. Maintain authorized-distributor procurement records (Allergan Aesthetics, Galderma direct).

Lever 12: Marketing diversification, FTC compliance, and review base

Current: 60%+ of new patients come from the owner’s personal social media following or word of mouth; under 4.5 Google rating; under 100 reviews; no paid acquisition; influencer relationships without documented #ad disclosures. Target: Under 30% from owner-tied sources; 4.7+ Google rating with 250+ reviews; mix of paid social (Meta, TikTok), Google Ads, SEO, email/SMS automation. Influencer marketing fully FTC-compliant with documented #ad disclosures and content review log. Impact: Owner-tied lead source is key-person risk by another name. Diversified, trackable marketing is what makes the demand engine transferable in PE underwriting. FTC influencer compliance is binary: FTC and FDA treat influencer content as company content for medical aesthetics, and undisclosed sponsorship plus unsupported clinical claims have triggered enforcement (FTC “Endorsements, Influencers, and Reviews” guidance; JD Supra “FTC Advertising Compliance for Med Spas” 2025; Hendershot Cowart 2025). Estimate: +0.25x to 0.75x multiple uplift from diversified, compliant marketing. How: Post-procedure SMS/email review request flow. Paid social under a marketing manager (not the owner). SEO investment 12+ months pre-sale. Documented influencer agreements with required #ad disclosures, content review log, and takedown records.

What PE Asks Before They Send an LOI (The Pre-LOI Diligence Stack)

Before a PE firm commits to a letter of intent, they ask for a focused diligence package. The list below is the real ask from 2026 PE platforms targeting medspas in CT Acquisitions’ pipeline, expanded with medspa-specific items sourced from Ankura, VMG Health, NERO, Hinshaw & Culbertson, Practice Transitions Group, and Aesthetic Brokers content. The sell process flows: Teaser to NDA to CIM to IOI to Management Meeting to LOI to Confirmatory DD to Definitive Purchase Agreement to Close (Colonnade Advisors podcast 020; Auxo Capital Advisors sell-side process guide 2025).

1. Income statements for 2024, 2025, and the latest trailing twelve months

Why PE asks: They are building the LTM EBITDA they will multiply. They want trend (growth rate, margin trajectory), seasonality, and any one-time movers. LTM is the bridge between the most recent year-end and today, so the headline price reflects current run-rate, not stale data. For medspa, PE looks for a “skin-first” vs. “injectable-first” revenue mix and the new GLP-1 weight-loss line (compounded semaglutide and tirzepatide) that can be 70% to 85% gross margin on the basic tier but carries FDA shortage-status volatility (ScaleHaven 2026; Ankura 2025). They will flag any line item that depends on a current FDA shortage carve-out.

How to prepare: Accrual-basis P&L by month, mapped to a clean chart of accounts. Service-line P&L (injectables vs. devices vs. laser vs. skincare retail vs. weight-loss vs. memberships) where possible. Reconcile to tax returns so there are no surprises in confirmatory diligence.

2. Balance sheet at the latest month

Why PE asks: Two reasons. First, to start sizing the working capital peg they will set in the purchase agreement. Second, to identify net debt and debt-like items. For medspa the biggest debt-like item is deferred revenue from prepaid service packages, gift cards, membership prepayments, and unredeemed Alle points credited to the patient ledger. Deferred revenue is one of the most contentious items in medspa M&A (Auxo Capital Advisors 2025; Ankura 2025). Sellers argue it is normal NWC; buyers argue it is debt-like because they inherit the obligation to deliver services without receiving new cash.

How to prepare: Tie the balance sheet to the trial balance. Isolate deferred revenue by source (prepaid packages, gift cards, memberships, redeemable loyalty points). Book at accrual, not cash, with ASC 606 alignment.

3. Add-back estimates

Why PE asks: They want a sneak peek at your adjusted EBITDA story before they sink diligence cost into the file. If your add-backs are aggressive or undocumented, they discount the rest of your numbers. Defensible medspa add-backs include owner compensation above market, owner-related medical director fees adjusted to FMV, legal fees tied to one-time CPOM restructure, non-recurring equipment write-offs, rebrand/website/signage, COVID-era ERC, one-time owner-family conferences.

How to prepare: Build the bridge from book EBITDA to adjusted EBITDA, line by line. Document every add-back with the underlying invoice or payroll record. What does NOT stick: discounting your patient base, expensing year-end injectable inventory (that is misstatement, not add-back), and reclassifying real recurring marketing spend (paid social, Google Ads, influencer fees) as “one-time” (Practice Transitions Group; Aesthetic Brokers; Liguori Accounting medspa W-2/1099 series).

4. Anonymized employee roster (titles, start dates, pay, classification)

Why PE asks: Two risks. First, provider concentration and turnover risk. Injectors with deep patient loyalty are the chassis of the practice. Second, W-2 vs. 1099 classification risk, which is a deal-killer in medspa because medical-supervision rules push toward W-2. Master injector compensation typically runs $80K to $130K base for RN, $150K to $300K+ for NP-injector with high book; commission structures of 15% to 30% of injectable revenue are common; aesthetician compensation typically $50K to $80K base + 15% commission (CFO Pro Analytics 2025; Pabau “Med Spa Compensation Strategies”; Boulevard “Medspa Nurse Salary Guide” 2026).

How to prepare: Roster columns should include role (MD, NP, PA, RN, LME, esthetician, admin), state license, hire date, FT/PT, W-2/1099 classification with rationale, base + commission + spiff structure, active non-compete and non-solicit duration plus geography. Calculate and disclose 12-month and 24-month rolling provider retention.

5. Revenue breakdown and average ticket by service mix

Why PE asks: This is the single most diagnostic exhibit. It tells them whether the practice is injectable-heavy (high margin, recurring 3 to 6 month cadence) or laser/device-heavy (more capital-intensive, less predictable repeat); whether average ticket is growing, flat, or declining (a flat or declining ticket is a pricing-discipline red flag); and whether repeat-visit cadences are growing (loyalty) or contracting (churn). Benchmarks: average revenue per visit recovered to $454 to $484 in 2025 (Zenoti 2025); industry-wide per-visit spend $536 (Ankura 2025 from AmSpa); top-tier ARPV benchmark $672.50 (FinancialModelsLab 2025). CoolSculpting Elite packages run $1,000 to $3,000; Morpheus8 $600 to $1,200/session typically sold in packages of 3 to 6 (MedSpaMillions 2025; Medicreations 2025).

How to prepare: Pull straight from Aesthetic Record, Boulevard, Symplast, Nextech, Pabau, or AestheticsPro. Three columns at minimum: total revenue by service line (injectables, energy devices, laser, skincare retail, memberships, GLP-1 weight-loss, IV therapy, hormone therapy), number of visits by service line, average ticket per service line, year over year, 2022 through 2025 + LTM.

6. Membership program snapshot (counts by month, ARR, renewal/churn, plan mix)

Why PE asks: Recurring revenue is the single biggest multiple driver in medspa M&A. They want absolute member count, MRR and ARR, churn / renewal rate, plan mix (basic vs. premium), average revenue per member, and the deferred revenue liability on the balance sheet from prepaid annual plans (which becomes a debt-like item at close). Industry-wide membership programs typically contribute 14% to 30% of total revenue (Pabau 2025; Vagaro 2026; Zenoti 2026; ProSpyrMed 2025). Medspas running active membership engines see MRR grow 40% to 60% in year one (Regulr.ai 2026). Average non-member visits 1.4x/year; average member visits 5.8x/year (ProSpyrMed 2025).

How to prepare: Member count by month for the last 36 months. Renewal rate calculation. ARPM. Plan-mix breakdown. ARR snapshot. Separate deferred revenue tracking on prepaid annual plans.

7. Five-year business plan

Why PE asks: PE underwrites a forward case (years 1 through 5 post-close). They want to see if you have a credible growth story and how aggressive you are. They will overlay their own model on top, but your plan tells them whether you understand your own levers. Medspa-specific: GLP-1 line growth assumption (will it survive FDA shortage normalization?), de novo location plans, new energy device additions, membership conversion targets, marketing-spend ramp.

How to prepare: A simple operating model: revenue by service line, gross margin assumptions, overhead growth, EBITDA. Include capacity build (provider headcount and treatment-room utilization), planned expansion territories or service lines, pricing actions, and any commercial pipeline.

8. Asset / device schedule

Why PE asks: Three reasons. CapEx forecast for device refresh (medspa devices have 5 to 7 year useful life and depreciate fast vs. the tech curve). Capital lease vs. owned vs. financed (leased equipment is debt-like and comes out of purchase price). Device manufacturer service contract status with BTL, Sciton, InMode, Allergan/AbbVie CoolSculpting, Cynosure, Cutera.

How to prepare: Spreadsheet with device, manufacturer, model, year purchased, purchase price vs. current book, ownership status (owned, financed, leased, residual), monthly payment if any, service contract status, calibration / safety inspection log.

9. Org chart + medical director agreement

Why PE asks: This is the single most diligence-intense item unique to medspa M&A. Buyers trace the medical director (MD/DO) all the way through the org chart, verify written delegation protocols, verify chart sign-off cadence, and verify CPOM-compliant MSO/PC structure in restrictive states.

How to prepare: Org chart showing PC (physician-owned) vs. MSO (management) with arrows for management fee flow. Written medical director agreement on file. Written delegation protocols for each procedure category (injectables, lasers, RF/microneedling, IV therapy, weight-loss prescribing). Sign-off log showing MD chart reviews.

10. Legal and regulatory history

Why PE asks: State medical board complaints, state pharmacy board complaints, FDA warning letters (rare but they happen), patient adverse-event records, malpractice claim history, FTC influencer disclosure compliance. Adverse event documentation is one of three areas buyers scrutinize most (NERO 2026; Hinshaw & Culbertson 2025). Issues here can cause buyers to walk away entirely, not just discount the multiple.

How to prepare: Pull complaint history from each state board you operate in. Build the adverse event log with chronology, follow-up notes, resolution. Audit FTC influencer disclosures (#ad, #sponsored placement must be unambiguous and unmissable, not buried in hashtag strings).

Confirmatory Diligence (After You Sign the LOI)

Once an LOI is signed and exclusivity starts (typically 45 to 90 days per Colonnade Advisors podcast 020), the buyer runs parallel workstreams. This is the depth of inspection your business will undergo. If anything was hiding, it surfaces here.

1. Quality of Earnings (QoE). Outside accounting firm runs revenue cut-off testing, deferred revenue analysis (huge for medspa because of prepaid packages, memberships, and gift cards), expense normalization, add-back validation, working capital trends. Output: an adjusted EBITDA number the buyer locks into the model.
2. Compliance and regulatory DD (medspa-specific). Medical director agreements, scope of practice review, adverse event documentation, CPOM structure if in a restrictive state, FTC influencer marketing compliance, OSHA medical-waste and sharps compliance, HIPAA and state privacy. NERO 2026 calls compliance “the new deal-killer.”
3. Provider concentration + commercial DD. Patient retention analysis by injector, top-injector revenue concentration, non-compete / non-solicit enforceability in operating states, provider compensation review.
4. IT systems audit. Aesthetic Record, Boulevard, Symplast, Nextech, Pabau, AestheticsPro. Data quality, integration capability with the platform’s stack, EMR completeness, license counts. PE platforms typically want acquired companies on the same EMR as the rest of the portfolio.
5. Legal. PC/PLLC and MSO good standing in every operating state, state medical board complaints, contracts assignment, IP (brand, social handles), litigation history, malpractice claims, real estate leases.
6. HR/Payroll. W-2 vs. 1099 classification audit (HIGH risk in medspa due to medical-supervision rules), wage-and-hour exposure, benefits, PTO accrual, EEOC/DOL claims, non-compete enforceability.
7. Tax. Federal income, payroll, sales/use (skincare retail is taxable in most states), property. Sales tax on services varies state by state and is a recurring exposure for medspas that sell retail skincare.
8. Product procurement audit (medspa-specific). Allergan and Galderma purchase records audited to verify all BOTOX, Juvederm, Restylane, and Dysport were procured through authorized distributors, not the gray market. Allergan-dropped accounts are functionally unsellable.

Why You Should Pay for Your Own Quality of Earnings Before Going to Market

A sell-side QoE is your own outside accountant’s QoE, paid for by you, before you go to market. For medspa it does four things specifically: pre-empts the buyer’s QoE by getting to the adjusted EBITDA number first with documentation; surfaces deferred revenue treatment for prepaid packages, gift cards, and memberships before the buyer turns it into a debt-like haircut; validates EBITDA add-backs including the medical director fee FMV adjustment and the owner-injector compensation normalization; and tightens the EBITDA number you take to market, which directly drives the headline price.

Cost

• $25K to $35K for QoE if revenue is below $5M and the chart of accounts is clean (Eton Venture Services 2025; Morgan & Westfield).
• $40K to $90K typical range for sell-side QoE on a medspa with multiple service lines, membership program, deferred revenue, and MSO/PC structure (Eton 2025; Kahn Litwin Renza buy-side vs. sell-side 2025; Ankura Transaction Advisory medspa engagements).
• $150K to $200K for medspas with complex add-backs, multi-entity MSO/PC structures across multiple states, GLP-1 lines with FDA shortage dependencies, or messy books (Eton 2025; Ankura 2025).

Medspa typically prices higher than HVAC ($35K to $75K) because of deferred revenue complexity, compliance dependencies, and the need for a healthcare-specific QoE provider. Providers with medspa or aesthetic specialization include Ankura, VMG Health, Eton Venture Services, Riveron, BDO, Skytale Group, and Physician Growth Partners.

ROI

Example: a $3M EBITDA medspa moving from 5x to 6x equals $3M of additional sale price. A $60K to $90K QoE investment that supports the 1x lift is a 33x to 50x return (synthesized from Eton “Quality of Earnings Report Cost”, 2025; Ankura medspa transaction experience). Medspa-specific example: a buyer’s QoE that uncovers $250K of unbooked deferred revenue (from prepaid packages) reclassifies that as debt-like at close, dropping purchase price by $250K. A sell-side QoE that surfaced the same item in advance lets the seller either book it correctly or carve it out of the deal cleanly.

Deal-Killers That Re-Trade Medical Spa Transactions (Avoid These)

These are the recurring kill-shots cited across medspa M&A advisory content and confirmatory diligence checklists. Most are fixable in 12 to 24 months. None are fixable in 30 days.

1. Non-compliant medical director arrangement (the #1 medspa-specific kill)

Each state has different rules. CA requires the medical director to have examined each patient (in practice, a written treatment plan signed off before delegating). NY follows a rigid CPOM interpretation; only physicians or physician-owned PCs/PLLCs may provide medical services, standing orders do not qualify, and the ordering provider must first examine the patient (Portrait Care; AmSpa NY summary; Spa Source). TX, effective Sept 1, 2025 via House Bill 3749, requires every medspa performing “cosmetic medical procedures” to appoint a medical director with specific training, with initial patient assessments and written treatment plans before delegating (McGuireWoods 2025; Pabau TX guide). NY State has begun explicit crackdowns on “paper medical directors” who lend names without actively overseeing practices, with surprise inspections and enforcement actions (Norman Spencer Law Group “Med Spas Under Fire” 2025). If the medical director arrangement is non-compliant, the practice is operating illegally and the acquirer walks.

2. Corporate Practice of Medicine (CPOM) structural violations

Most states restrict non-physician ownership of medical practices. Compliant structure is the MSO + PC model: physician owns the PC (which holds the medical practice license and employs providers); non-physician owns the MSO (which provides administrative services for an FMV fee). Fee-splitting risk: percentage-based MSO fees are risky (allowed in CA, banned in NY), while fixed or cost-plus fees are the safest path (Cohen Healthcare Law; LBMC “Understanding the MSO-PC Model”; Permit Health 50-State CPOM Guide). TX requires 51%+ ownership by a licensed physician under CPOM (StartPermit TX guide). CA allows non-physicians via MSO only if the MSO does not control clinical decisions. NY requires PC/PLLC structure authorized by NYSED. PE buyers will not close on a deal that has an unfixable CPOM violation, and the cost of restructure is non-trivial ($25K to $75K legal + ongoing FMV fees).

3. Product procurement through gray market or unauthorized distributors

Allergan and Galderma have explicit authorized-distributor programs. Practices that buy BOTOX, Juvederm, Restylane, or Dysport through unauthorized channels (overseas, online, third-party brokers below WAC) risk being dropped from authorized supply entirely, receiving counterfeit product (FDA issued a public warning April 2024 that counterfeit Botox was used in multiple states; CDC investigated adverse reactions across 9 states including CA; American Board of Cosmetic Surgery 2024), and patient harm liability. Allergan WAC for BOTOX Cosmetic is $656 per 100-unit vial as of Feb 2024; small medspas typically pay $500 to $600 through authorized distributors. Significantly lower prices from unfamiliar sources signal gray market (Meamoshop “Botox Wholesale Cost” 2026). PE buyer DD now includes a purchase-record audit. Allergan-dropped accounts are functionally unsellable.

4. Provider concentration and master-injector flight risk

If a single injector drives 30%+ of injectable revenue and patient loyalty is to that person, not the brand, the buyer treats the entire shop as flight risk. NERO 2026: “If key staff members walk away during the due diligence process or immediately post-acquisition, valuation collapses.” Weak or unenforceable non-competes compound the risk. CA does not enforce non-competes at all. FL and TX enforce with limits (geography, time, scope). Common buyer response: 12 to 24 month earn-out tied to provider retention plus rollover equity in the platform.

5. W-2 vs. 1099 misclassification (medspa-specific severity)

Medical-supervision requirements push toward W-2 (the provider operates under your protocols, your supervision, on your patients, with your equipment). 1099 classification of medical professionals raises CPOM concerns because it implies the provider is operating independently outside the PC’s supervision (Cohen Healthcare Law 2024; Weitz Morgan TX 2026; Liguori Accounting 2026). IRS settlements range $10K to $100K+ per misclassified worker once back taxes, penalties, interest, and legal cost are aggregated. Any single SS-8 filing by a former contractor opens a workforce-wide audit. DOL renewed enforcement focus in 2025 (PRN Healthcare 2024). Medspa-specific aggravator: state medical boards investigate medspas with 1099 injectors as a potential CPOM violation channel.

6. Deferred revenue accounting and prepaid package mismanagement

Cash-pay medspa model means prepaid packages, memberships, and gift cards are common. If revenue from these is booked at point of sale (cash basis) instead of when services are rendered (accrual basis with deferred revenue liability), the QoE will reclassify it and reduce the headline EBITDA you take to market (Ankura 2025; VMG Health 2025). Subsequent service usage from prepaid packages is sometimes booked as write-offs / discounts rather than amortization of prepaid balances, which inflates discount and depresses EBITDA (Ankura 2025). Buyer treats unredeemed deferred revenue as debt-like and pulls it out of purchase price.

7. Adverse event documentation gaps and informed consent failures

Each procedure category has state-specific informed-consent requirements (Hinshaw & Culbertson 2025). Adverse event documentation is one of three top areas under DD scrutiny (NERO 2026). Common gap: paper consents stored in physical files with missing signatures, no chronology of adverse events, no follow-up notes. Buyer cannot underwrite the litigation tail if records are incomplete.

8. FTC influencer marketing non-compliance

FTC treats influencer content as company content. Required disclosures (#ad, #sponsored) must be unambiguous and unmissable. Buried in hashtag strings does not count (FTC “Endorsements, Influencers, and Reviews” guidance; inBeat Agency 2025 update). FDA additionally regulates clinical claims (Hendershot Cowart 2025; Cohen Healthcare Law). Medspas with influencer-heavy marketing must document approved scripts, redlines, final assets, URLs, timestamps, disclosures, comment logs, corrections, takedowns, and submission records (Pharma Marketing Network 2025; XDS 2025). A single FTC warning letter in DD makes the deal much harder.

9. Sales/use tax exposure on retail skincare and services

Most states tax retail skincare products (Skinceuticals, Obagi, Alastin, SkinMedica). Many medspas under-collect because they treat retail as ancillary. Confirmatory tax DD surfaces multi-year exposure. Some states (PA, TX) tax service revenue itself depending on classification; PE buyers will run a sales-tax exposure analysis in confirmatory.

10. Insurance billing in a cash-pay practice

Some medspas bill insurance for medical procedures (excessive sweating with BOTOX therapeutic, weight-loss with PCOS diagnosis). This creates exposure under Stark Law, the Anti-Kickback Statute, False Claims Act, and HIPAA. Phantom billing, upcoding, and unbundling are all surfaced via billing DD (NCDS “Combating Medical Billing Fraud” 2024; Howley Law Firm; Hendershot Cowart 2026). PE buyers are wary of acquiring a practice whose owner-physician is liable for billing-company fraud (Hendershot Cowart 2026: “Physician Liability for Medical Billing Company Fraud”).

11. State medical board complaint history

Any pending complaint or settlement against the medical director, the owner-physician, or any provider gets surfaced in legal DD. Open complaints flag the deal. Closed complaints get evaluated. A pattern of complaints in the same procedure category (e.g. multiple filler complications) gets priced into the deal heavily.

12. Real estate / lease assignment friction

Many medspas occupy retail/office leases with personal guarantees, landlord-consent assignment clauses, and term mismatches to deal close. Lease assignment friction can drag a deal 30 to 90 days or force a holdback. Common in Class A retail in destination metros.

The 36-Month Exit Prep Timeline

T-36 months: Cleanup phase

• Switch to accrual basis if still on cash basis. Adopt ASC 606 alignment for service revenue and prepaid package amortization
• Pick a medspa EMR (Aesthetic Record, Boulevard, Symplast, Nextech, Pabau, AestheticsPro) and migrate. Plan for 3 to 9 month migration depending on scale
• Start tagging every potential EBITDA add-back as it happens
• Audit W-2 vs. 1099 classification; reclassify clinical staff to W-2 if needed and settle exposure proactively
• Restruck related-party rent to FMV with appraisal
• Build org chart with MSO/PC clearly separated. Get legal opinion on CPOM compliance in every operating state from healthcare counsel (Cohen Healthcare Law, Spencer Fane, Hinshaw & Culbertson, ByrdAdatto, Holt Law all run this engagement)
• Restruck medical director arrangement: written agreement, written delegation protocols, FMV opinion on MD fee, documented chart sign-off cadence
• Sales/use tax compliance review by outside counsel in every operating state
• Verify all product procurement runs through authorized distributors (Allergan, Galderma direct). Stop any gray-market buying immediately
• Build patient consent and adverse-event documentation in the EMR with mandatory fields

T-24 months: Financial discipline, KPI infrastructure, membership push

• Identify GM hire (internal promotion target or external recruit). Onboard 12+ months pre-sale
• Monthly close in 15 days; service-line P&L every month
• KPI dashboard: average ticket, visits per patient per year, member count + MRR + ARR + churn, injector utilization (75% to 85% target), aesthetician utilization (65% to 80% target), new patient acquisition cost by channel, review velocity
• Launch or relaunch membership program. Target trajectory: 14% baseline to 30% in 18 months
• Hire 2 to 3 additional W-2 injectors; cross-pollinate patient panels to spread provider concentration
• Build provider career ladder (Junior Injector, Senior Injector, Lead Injector, Clinical Director)
• Pricing review: hold injectable unit price discipline, eliminate provider discounting, refresh price book quarterly
• Document SOPs for every operational role
• Build the add-back bridge as a living document

T-12 months: QoE-ready close discipline, eliminate owner / provider dependence

• Owner steps out of injector chair to under 20% of injectable revenue
• GM running operations; owner doing under 30 hours/week clinical
• Owner takes a 2-week unplugged vacation as the stress test
• Run sell-side QoE with a healthcare-specialist firm (budget $40K to $90K)
• Tighten balance sheet: clean A/R, isolate deferred revenue by source, member liability schedule, gift card liability schedule
• Final org-chart review; backfill any gaps
• Final compliance scrub: medical director agreement, CPOM structure, W-2/1099, sales/use tax, FTC influencer compliance, OSHA / HIPAA
• Lock in 12 months of clean service-line P&L for the CIM
• Push to Allergan Diamond/Platinum and Galderma Aspire highest tier if not already there

T-6 months: Pre-marketing prep

• Engage M&A advisor (sell-side investment bank or M&A advisory firm specializing in medspa or healthcare). Specialists include Skytale Group, Physician Growth Partners, Practice Transitions Group, Triumphant Partners, MedSpa Business Broker, Aesthetic Brokers, Centergrowth, FOCUS Investment Banking (healthcare team), Breakwater M&A, BGL, Northborne Partners. Typical fee structure: $25K to $75K monthly retainer credited against success fee of 4% to 8% of EV
• CIM drafted from the QoE and operating model
• Teaser drafted (anonymized 1-pager)
• Buyer list finalized (CT Acquisitions’ medspa map identifies 25+ active sponsors as a starting list)
• Virtual data room populated with everything from the pre-LOI and confirmatory sections above
• Management presentation deck built and rehearsed

T-3 months: Go to market

• Teaser distributed; NDAs collected; CIMs distributed
• IOIs collected 2 to 3 weeks after CIM goes out
• Narrow to 4 to 6 finalists for management meetings
• Management meetings; LOIs solicited
• Select LOI; sign with exclusivity (typically 45 to 90 days)
• Enter confirmatory diligence; close

End-to-end from engagement to close: typically 6 to 12 months for medspa, with 9 months as the well-run-process baseline (Practice Transitions Group; Aesthetic Brokers; Triumphant Partners; Auxo Capital Advisors 2025).

Frequently Asked Questions

How long should I plan for before selling my medical spa to a private equity buyer?

The owners who get top-quartile pricing start preparing 24 to 36 months before going to market. The minimum useful prep window is 12 months, because most of the high-leverage levers (lifting membership penetration from 14% to 30%+, installing a GM, getting on a modern medspa EMR, restructuring the MSO/PC and medical director arrangement, reclassifying 1099 clinical staff to W-2, running a sell-side QoE) need 12+ months of clean trailing-twelve-months data to be credible to a buyer. Owners who try to sell in under 6 months typically leave 20% to 40% of enterprise value on the table.

What is a realistic EBITDA multiple for a $2M EBITDA medical spa in 2026?

For a $2M EBITDA medspa in 2026, the range is 5x to 8x at the single- or two-location tier with 15%+ growth and a real management layer (Scope Research 2025; Breakwater M&A 2026). The bottom of that range applies to single-location, owner-injector-dependent shops with under 14% membership penetration, weak compliance documentation, and concentrated provider risk. The top applies to multi-provider, multi-location, 30%+ membership penetration, documented MSO/PC structure, GM in place, modern medspa EMR. Cross-vertical tie-ins to dermatology or plastic surgery can push toward the 7x to 9x platform-quality range (Breakwater M&A 2026; FOCUS Investment Banking 2026). At $20M+ revenue with brand equity and recurring base, the range shifts to 7x to 12x (Scope Research 2025; FOCUS Bankers 2026). The 36-month prep playbook is what moves you from the bottom of the band to the top.

What percentage of membership revenue do PE buyers want to see?

30% or higher is the threshold that moves your business into the premium pricing tier per FOCUS Investment Banking 2026 and Breakwater M&A’s “recurring revenue + 15%+ growth” criterion. Industry-average membership penetration sits at 14% (Pabau 2025; Vagaro 2026), so getting to 30% requires a deliberate 18 to 24 month membership-conversion program. Members visit 2.9x more often, spend 35% more per visit, and represent 4.8x more lifetime value than per-visit clients (ProSpyrMed 2025; Boulevard “Average Med Spa Revenue” 2025). On a $1.5M EBITDA medspa, getting to 30%+ recurring is worth 0.5x to 1.0x in multiple uplift, or $750K to $1.5M of additional sale price (FOCUS Bankers 2026).

Should I get a quality of earnings report done before going to market?

For medical spas at $1M+ EBITDA, yes. A sell-side QoE costs $40K to $90K typical for a medspa with multiple service lines, a membership program, deferred revenue, and an MSO/PC structure (Eton Venture Services 2025; Ankura Transaction Advisory 2025), up to $150K to $200K for complex multi-state structures. The ROI is leverage. If your QoE supports a 1x multiple uplift on a $3M EBITDA medspa at a 5x baseline, that is $3M of additional sale price for a $60K to $90K investment, a 33x to 50x return. More importantly, a pre-market QoE surfaces deferred revenue treatment, medical director fee FMV, and owner-injector compensation normalization while you can still fix them, rather than during exclusivity when the buyer re-trades the deal.

Will private equity keep my injectors and providers after they buy my practice?

Yes, with conditions. Provider retention is the chassis of medspa value, and buyers structure transactions to lock providers in. Most 2025 medspa transactions were structured as 60% cash at close + 40% rollover equity, ranging up to 80% cash + 20% rollover, with holdbacks and earnouts tied directly to provider retention (AmSpa “Med Spa M&A and Private Sales: A Look Back at 2025”). The common buyer response to single-injector concentration above 30% is a 12 to 24 month earn-out tied to that provider staying plus rollover equity in the platform. If key providers walk during confirmatory diligence or immediately post-acquisition, the buyer either re-trades the deal heavily or terminates entirely (NERO 2026). The work to do pre-sale is bring in 2 to 3 W-2 injectors 18+ months before going to market and cross-pollinate patient panels so no single provider holds 30%+ of injectable revenue.

What is the medical director arrangement that buyers actually require?

Buyers require a documented MSO/PC structure with a written medical director agreement, written delegation protocols for every procedure category, a documented chart sign-off cadence, and a medical director fee at fair market value (typically $30K to $80K annually, with a written FMV opinion on file). In CPOM-restrictive states (CA, NY, TX, and others) the physician must own the PC; the non-physician owns the MSO; the MSO management fee must be fixed or cost-plus (percentage-of-revenue fees are allowed in some states but banned in others) (Cohen Healthcare Law; Permit Health 50-State CPOM Guide; Guardian Medical Direction). NY State has begun explicit crackdowns on “paper medical directors” who lend names without active oversight, with surprise inspections (Norman Spencer Law Group “Med Spas Under Fire” 2025). TX, effective Sept 1, 2025 via HB 3749, requires every medspa to appoint a medical director with specific training (McGuireWoods 2025). NERO 2026 calls compliance “the new deal-killer” and Hinshaw & Culbertson 2025 explicitly state: “Issues in any of these areas do not just reduce your multiple, they can cause buyers to walk away entirely.”

What to Do Next

The medical spa owners who get the top-quartile multiple all do the same three things. They start preparing 24 to 36 months before they want to be out. They get the MSO/PC structure and medical director arrangement bulletproof in every operating state before a buyer ever sees a CIM. And they bring in 2 to 3 W-2 injectors plus a GM 18+ months pre-sale so provider concentration is no longer a flight risk by the time confirmatory diligence starts.

Medical spa is the highest-multiple healthcare-services PE lane right now because it is cash-pay (no insurance billing friction), membership-recurring (the Alle Skincare Society loyalty model and custom in-house memberships compound retention), and high gross margin (BOTOX and filler injectables run 70%+ GM). Platform-quality medspas trade at 10x to 14x+ EBITDA. The recent Princeton / Allura Dec 2025, Alpha Aesthetics $93M Jan 2026, AMP / Avelure May 2026, and Hidden Harbor $850M continuation 2025 deals anchor the cycle. The capital is there. The question is whether your business is in shape to capture the top of the multiple band when you go to market.

If you are 12+ months from a potential exit and want a structured pre-sale optimization roadmap, CT Acquisitions has aesthetics operations specialists in our partner network who run multi-quarter prep engagements. If you are 6 to 12 months out and ready to start the sell-side process, our M&A advisory team runs the buyer outreach. Buyers pay our fee, not you. Either way, the first 30 minutes are free.